摘要
本研究通过回顾性分析,探讨伊尼妥单抗与其他靶向药物联合治疗1例人类表皮生长因子受体2(HER2)阳性复发转移乳腺癌病例的有效性。患者为一名59岁女性,在(新)辅助治疗阶段接受过曲妥珠单抗治疗,后于2020年12月诊断为乳腺癌术后颈部淋巴结转移和骨转移。在晚期一线治疗中,患者接受了白蛋白紫杉醇联合伊尼妥单抗和帕妥珠单抗的治疗方案,获得了近15个月的无进展生存期(PFS)。在晚期二线治疗中,采用了吡咯替尼联合卡培他滨的方案,PFS已超过20个月,且患者的耐受性良好。该治疗方案为经曲妥珠单抗治疗后复发的HER2阳性乳腺癌晚期一线患者带来了良好的生存获益,相关文献复习也支持了本研究的结论。本研究为临床医生提供了新的治疗策略和方法,有助于提高HER2阳性乳腺癌患者的治疗效果和生活质量。但是,仍需进行更多临床试验来进一步验证该治疗方案的有效性和安全性。
This study explored the effectiveness of combining Inetetamab with other targeted drugs in treating a case of Hu-man epidermal growth factor receptor 2(HER2)-positive recurrent metastatic breast cancer through retrospective analysis.The patient was a 59-year-old woman who received Trastuzumab during the neoadjuvant treatment period,and was diag-nosed with breast cancer with cervical lymph node metastasis and bone metastasis in December 2020.In the late first-line treatment,the patient received a regimen of albumin-bound paclitaxel combined with Inetetamab and Pertuzumab,achieving a nearly 15-month progression-free survival(PFS).In the late second-line treatment,a regimen of Pyrotinib combined with Capecitabine was used,with PFS exceeding 20 months and good tolerability.This treatment regimen brought good survival benefits to patients with HER2-positive breast cancer who relapsed after Trastuzumab treatment,and relevant literature re-views also supported the conclusion of this study.In summary,this study provides clinicians with new treatment strategies and methods that can help improve the treatment effect and quality of life of patients with HER2-positive breast cancer.However,more clinical trials are still needed to further verify the effectiveness and safety of this treatment regimen.
作者
张明坤
张聚良
ZHANG Mingkun;ZHANG Juliang(Department of Thyroid and Breast Vascular Surgery,Xijing Hospital,Air Force Medical University of Chinese People's Liberation Army,Shaanxi Province,Xi'an 710032,China)
出处
《中国当代医药》
CAS
2024年第9期149-152,共4页
China Modern Medicine
基金
中国抗癌协会-HER2靶点中国科研基金项目(CORP-239)。
关键词
HER2阳性乳腺癌
伊尼妥单抗
吡咯替尼
无进展生存期
Human epidermal growth factor receptor 2 positive breast cancer
Inetetamab
Pyrotinib
Progressive free survival
作者简介
通讯作者:张聚良。
